|1.||Guengerich, F Peter: 1 article (08/2011)|
|2.||Murayama, Norie: 1 article (08/2011)|
|3.||Komori, Masayuki: 1 article (08/2011)|
|4.||Shimada, Tsutomu: 1 article (08/2011)|
|5.||Yamazaki, Hiroshi: 1 article (08/2011)|
|6.||Takenaka, Shigeo: 1 article (08/2011)|
|7.||Tanaka, Katsuhiro: 1 article (08/2011)|
|8.||Sinha, Raghu: 1 article (03/2006)|
|9.||El-Bayoumy, Karam: 1 article (03/2006)|
|10.||Pinto, John T: 1 article (03/2006)|
09/01/1991 - "Benzyl selenocyanate (BSC), a synthetic organoselenium compound, has been shown to inhibit chemically induced tumors in several animal model systems. "
09/01/1995 - "We previously demonstrated that while both benzyl selenocyanate (BSC) and 1,4-phenylenebis(methylene)selenocyanate (p-XSC) have high efficacy as cancer chemopreventive agents in several animal tumor models, p-XSC is less toxic. "
08/01/1985 - "Benzylthiocyanate showed no significant inhibitory effect, but benzylselenocyanate reduced the number of tumors per animal from 3.3 to 1.7 (P less than 0.01). "
04/01/1998 - "The organoselenium compounds benzyl selenocyanate (BSC) and 1,4-phenylenebis(methylene)selenocyanate (p-XSC), as well as sodium selenite, are effective chemopreventive agents for various chemically induced tumors in animal models at both the initiation and postinitiation stages. "
03/01/2006 - "In addition, benzyl selenocyanate inhibited the development of DMBA-induced mammary adenocarcinomas and azoxymethane-induced colon cancer in rats and benzo[a]pyrene-induced forestomach tumors in mice. "
|2.||Aberrant Crypt Foci
07/01/1998 - "We have assessed the chemopreventive properties of a newly synthesized organoselenium compound, benzyl selenocyanate glutathione conjugate (BSeSG), and of benzyl selenocyanate (BSC), as a positive control, using azoxymethane (AOM)-induced colonic aberrant crypt foci (ACF) as a measure of efficacy. "
11/01/1994 - "As a part of a program aimed to develop less toxic and more effective chemopreventive organoselenium compounds than inorganic selenium, we have evaluated benzyl selenocyanate (BSC) and its o-, m-, p-nitro and -methoxy isomers, o-, m-, and p-isomers of phenylenebis(methylene)selenocyanate (XSC), dibenzyl diselenide (DDS), and 2,2'-diselenobis[((N,N-dimethylamino)methyl)- benzene]bis(hydrochloride salt) (DSBDB) for their potential colon tumor inhibitory properties using azoxymethane (AOM)-induced colonic aberrant crypt foci (ACF), a preneoplastic lesion, in male F344 rats prior to preclinical efficacy study. "
|3.||Colonic Neoplasms (Colon Cancer)
|4.||Chromosome Aberrations (Chromosome Abnormalities)
10/01/1990 - "The ability of 2 synthetic organoselenium compounds, a dimer of p-methoxybenzeneselenol (DPMBS) and benzylselenocyanate (BSC), to induce sister-chromatid exchanges (SCE) and chromosome aberrations (CA) as well as to alter the progression of the cell through mitosis has been investigated in cultured human lymphocytes. "
|6.||selenocyanic acid (selenocyanate)
|8.||Sodium Selenite (Selenite)
|10.||Aromatic Polycyclic Hydrocarbons (Polycyclic Aromatic Hydrocarbons)